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thopaedic Translation (JOT), Cecchi and colleagues
describe the signalling pathways that bone morphogenetic
protein 7 (BMP-7) uses to exert its effect on bone, as well as
its efficacy to promote fracture healing [1]. Thanks to
supportive preclinical and clinical data, rhBMP-7 (also
known as osteogenic Protein-1) has received approval from
the Food and Drug Administration and it is now commer-
cially available. Donor-site morbidity, volume constraints,
and infection commonly associated with autogenous bone
grafting (ABG) has made rhBMP-7 an attractive alternative
for the stimulation of bone formation, particularly in the
nonunion of bone, where recent studies indicate similar
efficacy to ABG. Also of interest in this context, the com-
bination of rhBMP-7 with ABG has been studied and found to
show higher rates of fracture healing than either method
alone [2].
Antisclerostin antibodies, a novel promising
treatment option for osteoporosis
Also in this issue of JOT, you will find several articles with a
focus on novel anti-osteoporotic treatment options. The
review article written by Suen and Qin is dedicated to
sclerostin [3], a bone anabolic treatment that is perhaps
the most promising emerging therapeutic target for the
treatment of osteoporosis and osteoporotic fracture. At
present, osteoanabolic therapy is limited to the use of
parathyroid hormone 1e84 (PTH [1e84]) and its biologicallyhttp://dx.doi.org/10.1016/j.jot.2015.12.001
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).active 34-residue amino-terminal fragment known as ter-
iparatide (PTH [1e34]). When administered intermittently
(once daily), these PTH molecules are osteoanabolic [4,5].
However, PTH has certain disadvantages such as the need
for daily self-injections, high cost, requirement for refrig-
eration, a 2-year limit to its use and the US FDA-mandated
boxed warning concerning osteosarcoma in rats in preclin-
ical toxicity studies [6]. Furthermore, the increase in bone
formation seen with PTH treatment is often followed by an
increase in bone resorption, resulting in an ‘undesired’ in-
crease in bone remodelling. The development of other
classes of osteoanabolic drugs, such as the antisclerostin
antibodies described by Suen and Qin [3], which, in contrast
to PTH, are associated with a reduction in bone resorption,
is thus highly desirable. Results from a randomized, double-
blind, placebo-controlled multicentre Phase 2 clinical trial
of blosozumab, a humanized monoclonal antibody targeted
against sclerostin, in postmenopausal women with low bone
mineral density (BMD) were reported recently [7]. In-
jections of blosozumab for 1 year resulted in substantial
anabolic effects on the skeleton and were well tolerated.
These results were similar to those reported earlier for
romosozumab (AMG 785) [8,9]. Further evaluation of the
efficacy of these agents including fracture end-points, and
of their safety in large Phase III controlled studies are
eagerly awaited. The transition from PTH to antisorptive
therapy after 2 years is predicated on FDA and other na-
tional regulations limiting its use to this period of time. In
analogy, for antisclerostin antibodies, sequential treatment
to follow the osteoanabolic treatment with an anti-
resorptive drug for long-term preservation seems an
attractive possibility.
The problem with available long-term treat-
ment options for osteoporosis
Currently, no treatment can completely reverse established
osteoporosis and all available antiresorptive treatment
options are limited in the duration of their use. Early
intervention can prevent osteoporosis in most people. For
patients with established osteoporosis, medicalore) Pte Ltd. This is an open access article under the CC BY-NC-ND
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porosis is present, treatment for the primary disorder
should be provided. Therapy should be individualized based
on each patient’s clinical scenario, with the risks and
benefits of treatment discussed between the clinician and
patient [10]. According to a clinical practice guideline by
the American College of Physicians, because of the signifi-
cant disability, morbidity, mortality, and expenses associ-
ated with osteoporotic fractures, treatment is aimed at
fracture prevention [11]. Guidelines for osteoporosis
treatment are also available from the American Association
of Clinical Endocrinologists [12] and from a combined effort
undertaken recently by the International Osteoporosis
Foundation and European Society for Clinical and Economic
Aspects of Osteoporosis and Osteoarthritis [13]. Preventive
measures include modification of general lifestyle factors,
such as increasing weight-bearing and muscle-
strengthening exercise, which have been linked to frac-
tures in epidemiologic studies, and ensuring optimum cal-
cium and vitamin D intake as an adjunct to active
antifracture therapy [14]. Medical care includes the
administration of adequate calcium, vitamin D, and anti-
osteoporotic medication such as bisphosphonates, the Re-
ceptor Activator of NF-kB Ligand (RANKL) inhibitor
denosumab (Dmab), parathyroid hormone, raloxifene,
strontium ranelate and until recently, oestrogen [12,13]. A
substantial number of different treatment options have
become available, raising the question as to whether or not
additional efforts should still be undertaken to develop
novel strategies for intervention? One of the challenges of
the currently used antiresorptive treatment options is that
for reasons of safety, or lack of long-term antifracture
data, they are all limited in their duration of use. This may
provide an opportunity for strategies presented in this issue
of JOT (Su et al [15]; Luo et al [16]; Chen et al [17]) which
are all based on Chinese traditional herbal medicines. So
what are the limitations of existing antiresorptive therapies
that these alternative treatment options would have to
overcome, and what are the gaps that must be filled before
they can be recommended for widespread clinical use in
osteoporosis?
Bisphosphonates are the mainstay of osteoporosis ther-
apy with robust data from numerous placebo-controlled
trials demonstrating efficacy in fracture risk reduction over
3e5 years of treatment [18]. Although bisphosphonates are
generally safe and well tolerated, concerns have emerged
about adverse effects related to their long-term use. Spe-
cifically, the continued use of bisphosphonates after 5 years
is associated with an increased risk of otherwise rare
atypical femoral fractures (AFF), osteonecrosis of the jaw
(ONJ), and oesophageal cancer. The incidence of ONJ is
greatest in the oncology patient population (1e15%), where
high doses of these medications are used at frequent in-
tervals [19]. In contrast, in the osteoporosis patient popu-
lation, the incidence of ONJ is estimated at 0.001% to
0.01%, marginally higher than the incidence in the general
population (<0.001%). Recently, ONJ has been identified in
bisphosphonates-naı¨ve patients receiving Dmab [20], which
necessitated accommodation of Dmab in the definition.
Although an association between bisphosphonates or Dmab
use and ONJ seems likely, a causal relationship with
bisphosphonate or Dmab therapy has not been established[19]. Another concern is that studies with radiographic re-
view consistently report significant associations between
AFFs and bisphosphonates use, even though the strength of
associations and magnitudes of effect vary [21]. The abso-
lute risk of AFFs in patients on bisphosphonates is low,
ranging from 3.2 to 50 cases per 100,000 person-years.
However, long-term use may be associated with higher risk
(100 per 100,000 person-years). Bisphosphonates appear to
localize in areas that are developing stress fractures. It has
been hypothesized that suppression of targeted intra-
cortical remodelling at the site of an AFF could impair the
processes by which stress fractures normally heal. In sup-
port of this hypothesis, when bisphosphonates are stopped,
risk of an AFF may decline.
Concerning long-term efficacy of bisphosphonates, ex-
amination of studies where bisphosphonates had been
administered for at least 3 years, and for which fracture
data were compiled, revealed that bone mineral density at
the femoral neck and lumbar spine was maintained but
without a consistent reduction in fracture rate [22]. Taken
together, these findings led the FDA to issue revised rec-
ommendations for the use of these drugs after 3 to 5 years
[23,24]. The new FDA recommendation indicated in revised
labelling states that, “the optimal duration of use has not
been determined. The need for continued therapy should
be re-evaluated on a periodic basis.” However, no specific
limits on the duration of treatment were imposed. The FDA
review noted that “there is no agreement on the extent to
which cumulative use of bisphosphonates increases the
risk” of atypical fractures.
Because bisphosphonates accumulate in bone with some
persistent antifracture efficacy after therapy is stopped, it
is reasonable to consider a ‘drug holiday’. There is
considerable controversy regarding the optimal duration of
therapy and the length of the holiday, both of which should
be based on individual assessments of risk and benefit [18].
It is against this background that the idea to replace strong
suppressors of bone remodelling such as bisphosphonates or
the RANKL inhibitor Dmab with less strongly active drugs for
long-term management of osteoporosis patients may
become an attractive alternative to simply stopping treat-
ment and leaving patients exposed to an increased fracture
risk.
The ‘mild’ alternatives to strong anti-
resorptives for long-term treatment of
osteoporosis?
In this issue of JOT, two ‘milder’ treatment options, namely
extracts from Alpinia officinarum (AOH) (Su et al [15]) and
Epimedii Folium (Chen et al [17]), that are used in tradi-
tional Chinese medicine are presented, which may provide
an alternative for long-term treatment of osteoporosis pa-
tients. In their study in ovariectomized rats (OVX), Su and
colleagues [15] demonstrated that extracts of AOH exerted
a mild antioxidant effect, increased bone formation and
showed mild antiresorptive properties. Partial reversal of
bone loss was achieved, and it remains to be seen whether
it is possible to optimize the extraction procedure to enrich
the active ingredients in order to achieve a more pro-
nounced effect on bone, while maintaining the favourable
Editorial 73profile on the uterus. In a direct comparison of Xian Ling Gu
Bao (XLGB) capsules containing two different Epimedium
species, namely Epimedium pubescens (XEP) or Epimedium
koreanum (XEK), Chen et al [17] reported that both XLGB
capsules were equally effective for the prevention of
oestrogen-depletion induced osteoporosis in a rat OVX
model. In vitro results suggested that all of the six com-
pounds contained in XEP and XEK might contribute to the
antiosteoporotic effects of the two XLGB formulae and
result in a comparable efficacy of XEP and XEK. In line with
a previous report, epimedin C was identified as the main
component of XEP, while icariin is the main flavonoid in
XEK. It should be noted that the use of XLGB capsules was
officially approved by the Chinese State Food and Drug
Administration as an over-the-counter drug for the treat-
ment of osteoporosis, osteoarthritis, aseptic osteonecrosis,
and fractures. In the first ever multicentre and randomized
clinical trial of herbal Fufang, daily oral XLGB was safe in
postmenopausal women when administered over a 1-year
treatment period [25]. Patients (nw50) treated with XLGB
demonstrated a statistically significant but mild increase in
dual-energy X-ray absorptiometry BMD at the lumbar spine
at 6 months, and a numerically increased BMD at 12
months. However, there was no dose-dependent response.
Also, bone turnover marker levels declined during the first 6
months after XLGB treatment, a difference no longer
observed at 12 months. There was no significant difference
in the overall incidence of side effects among treatment
and control groups. In spite of these encouraging results,
future clinical studies with longer duration will be required
to address the question raised by the biphasic BMD response
and transient effects of Fufang on bone turnover markers
[25]. Study endpoints will have to include the clinical ex-
amination of oestrogen-dependent tissues as well as frac-
tures as a study endpoint before this herbal medicine can
be recommended for the prevention or treatment of oste-
oporosis [26].
Also in this issue of JOT, Luo et al [16] describe the ef-
fect of tanshinol, a polyphenolic water-soluble component
of the traditional Chinese medicine Salvia miltiorrhiza
Bunge. When tested in larval zebrafish, tanshinol stimu-
lated bone formation and attenuated dexamethasone-
induced inhibition of osteogenesis. The authors provide
evidence that tanshinol protects organisms against oxida-
tive stress elicited by dexamethasone via scavenging of
excessive accumulation of reactive oxygen species gener-
ation, and simultaneously attenuates the inhibitory effect
of dexamethasone on osteoblastic differentiation and
mineral formation. In a previously published study, Cui et al
showed that salvianolic acid B, a polyphenolic component
of Salvia miltiorrhiza Bunge, prevented bone loss in
prednisone-treated rats through stimulation of osteo-
genesis and bone marrow angiogenesis [27]. Like AOH,
salvianolic acid B seems to combine antioxidant effects
with mild antiresorptive and bone formation stimulating
properties.
Eventually, improved preparations of herbal medicines
will have to be tested to establish their safety, before
clinical trials can be initiated to establish an active dose
and test their antifracture efficacy in adequately powered
Phase 3 trials [26]. In the absence of proven antifracture
efficacy, it is unlikely that herbal medicines will gainwidespread use in the treatment of osteoporosis, either as
stand-alone long-term treatment options or for the pres-
ervation of bone following withdrawal from anabolic ther-
apy with PTH or antisclerostin antibodies.
Finally, reported in this issue of JOT, Kamer and col-
leagues [28] computed 3D statistical bone and averaged
bone density models with low, middle and high total vBMDs,
using an extended, standard high-resolution peripheral
quantitative computed tomography (HR-pQCT) protocol to
image intact postmortem samples of the proximal humerus.
3D patterns of the size and shape variations were analysed
using principal component analysis in addition to the vBMD
distributions and variabilities using volume rendering and
virtual bore probing. New anatomical 3D data is expected
to improve our understanding of the normal bony anatomy
of the proximal humerus. In addition, the extended HR-
pQCT protocol and computer models proposed by Kamer
et al [28] might be used for other skeletal sites and serve as
3D reference models that can be applied to systematically
improve implant design and anchorage.
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